Post-translational modification of proteins and the discovery of new medicine

Current Opinion in Biotechnology

Volumn 8, Issue 6, 1997, Pages 718-723

  Parekh, Raj B ^a   Rohlff, Christian ^a  

^a Oxford GlycoSciences Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RNA;

DISEASE ACTIVITY; DRUG DEVELOPMENT; PRIORITY JOURNAL; PROTEIN MODIFICATION; REVIEW; RNA TRANSLATION;

EID: 0030725323     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(97)80126-7     Document Type: Article

References (74)

1. Cowburn D. Src homology adaptor proteins: more than the sum of the parts. Structure. 3:1995;429-430.
2. Bennett KL, Modrell B, Greenfield B, Bartolazzi A, Stamenkovic I, Peach R, Jackson DG, Spring F, Aruffo A. Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J Cell Biol. 131:1995;1623-1633.
3. Bartolazzi A, Nocks A, Aruffo A, Spring F, Stamenkovic I. Glycosylation of CD44 is implicated in CD44-mediated cell adhesion to hyaluronan. J Cell Biol. 132:1997;1199-1208.
4. 2+/calmodulin. J Biol Chem. 271:1996;1089-1095.
5. Rudd PM, Dwek RA. Glycosylation: heterogeneity and the 3D structure of proteins. of outstanding interest Crit Rev Biochem Mol Biol. 32:1997;1-100 A comprehensive review on the current understanding of the factors that control glycosylated variants of a single polypeptide. The authors illustrate, using several examples, the putative role that such heterogeneity may have in specific biological interactions.
6. Morello JP, Bouvier M. Palmitoylation: a post-translational modification that regulates signalling from G-protein coupled receptors. of special interest Biochem Cell Biol. 74:1996;449-457 This review discusses the biological importance of the dynamic palmitoylation of G-protein-coupled receptors and their cognate G proteins and geranylgeranylation of G proteins in receptor phosphorylation and desensitization.
7. Kawate N, Peegel H, Menon KM. Role of palmitoylation of conserved cysteine residues of luteinizing hormone/human choriogonadotropin receptors in receptor down-regulation. Mol Cell Endocrinol. 127:1997;211-219.
8. Horstmeyer A, Cramer H, Sauer T, Muller-Esterl W, Schroeder C. Palmitoylation of endothelin receptor A. Differential modulation of signal transduction activity by post-translational modification. J Biol Chem. 271:1996;20811-20819.
9. Pickering DS, Taverna FA, Salter MW, Hampson DR. Palmitoylation of the GluR6 kainate receptor. Proc Natl Acad Sci USA. 92:1995;12090-12094.
10. Hayashi MK, Haga T. Palmitoylation of muscarinic acetylcholine receptor m2 subtypes: reduction in their ability to activate G proteins by mutation of a putative palmitoylation site, cysteine 457, in the carboxyl-terminal tail. Arch Biochem Biophys. 340:1997;376-382.
11. Gibbs JB, Oliff A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. of outstanding interest Annu Rev Pharmacol Toxicol. 37:1997;143-166 The authors give a detailed review on one of the first small molecule inhibitors rationally designed based on studies of oncogenes that might advance to a novel cancer therapeutic. The article covers structures of farnesyl transferase inhibitors, their efficacy and selectivity for tumour cells in vitro and in vivo. It also addresses issues on other biological activities and limitations of these inhibitors.
12. Johnson LN, O'Reilly M. Control by phosphorylation. Curr Opin Struct Biol. 6:1996;762-769.
13. Hunter T. Oncoprotein networks. of outstanding interest Cell. 88:1997;333-346 This review discusses principles of cell regulation through recent examples of oncoproteins and tumour suppressor proteins to illustrate a regulatory network of growth factor- and growth inhibitory-initiated signaling pathways whose imbalance are a fundamental cause of cancer. The paper also clarifies the important principle of protein-tyrosine kinase dimerization in their activation process. Furthermore, it stresses the important role of the rho family and small G proteins, the cytoskeleton and the mitogen-activated protein kinase pathway in cellular transformation.
14. of special interest Faux MC, Scott JD. More on target with protein phosphorylation: conferring specificity by location. of outstanding interest Trends Biochem Sci. 21:1996;312-315 The article complements the review by Hunter, 1997 [13], and adds another layer of complexicity to regulation through protein phosphorylation. It surveys the increasing list of proteins targeting protein phosphatase 1 and 2 A, protein kinase C (PKC), PKC substrates, activated PKC, protein kinase A and multi-enzyme signaling complexes to a particular cellular compartment.
15. Sigal CT, Zhou W, Buser CA, McLaughlin S, Resh MD. Amino-terminal basic residues of Src mediated membrane binding through electrostatic interaction with acidic phospholipids. Proc Natl Acad Sci USA. 91:1994;12253-12257.
16. Li S, Couet J, Lisanti MP. Src tyrosine kinases, Gα subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem. 271:1996;29182-29190.
17. Lee FS, Hagler J, Chen ZJ, Maniatis T. Activation of the IκB α kinase complex by MEKK1, a kinase of the JNK pathway. Cell. 88:1997;213-222.
18. Van Delft S, Govers R, Strous GJ, Verkleij AJ, van Bergen en Henegouwen PM. Epidermal growth factor induces ubiquitination of Eps15. J Biol Chem. 272:1997;14013-14016.
19. Tsurumi C, Shimizu Y, Tanaka K. Degradation mechanism of cell cycle factors by the proteasome. Nippon Rinsho. 54:1996;861-869.
20. Alessandrini A, Chiaur DS, Pagano M. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia. 11:1997;342-345.
21. Nagata S. Apoptosis by death factor. of special interest Cell. 88:1997;355-365 The focal point of this paper is apoptosis controlled by cytokines and compares the signal cascade of the two death factors Fas ligand and tumor necrosis factor and their receptors. It also summarises the downstream cascade of interleukin-1β converting enzyme proteases and describes Fas mediated killing during activation induced suicide of T-cells, CTL-mediated killing of target cells and killing of inflammatory cells in immune privilege sites.
22. Rosen A, Casciola-Rosen L. Macromolecular substrates for the ICE-like proteases during apoptosis. J Cell Biochem. 64:1997;50-54.
23. Milczarek GJ, Martinez J, Bowden GT. p53 phosphorylation: biochemical and functional consequences. Life Sci. 60:1997;1-11.
24. Erhardt P, Tomaselli KJ, Cooper GM. Identification of the MDM2 oncoprotein as a substrate for CPP32-like apoptotic proteases. J Biol Chem. 272:1997;15049-15052.
25. Shaw P, Freeman J, Bovey R, Iggo R. Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene. 12:1996;921-930.
26. Han I, Kudlow JE. Reduced O-glycosylation of Sp1 is associated with increased proteasome susceptibility. Mol Cell Biol. 17:1997;2550-2558.
27. Hart GW, Kreppel LK, Comer FI, Arnold CS, Snow DM, Ye Z, Cheng X, DellaManna D, Caine DS, Earles BJ, et al. O-GlcNAcylation of key nuclear and cytoskeletal proteins: reciprocity with O-phosphorylation and putative roles in protein multimerization. of outstanding interest Glycobiology. 6:1996;711-716 The role of dynamic O-GlcNAcylation of cystosolic and nuclear proteins is examined and its implication in transcriptional initiation, cytoskeletal assembly and organization are discussed. A model of a reciprocal relationship between phosphorylation of a hydroxyl moiety and its O-GlcNAcylation is illustrated on c-myc and is being discussed based on examples of protein post-translational modifications in mitogen activated lymphocytes.
28. Jiang MS, Hart GW. A subpopulation of estrogen receptors are modified by O-linked N-acetylglucosamine. J Biol Chem. 272:1997;2421-2428.
29. Arnold CS, Johnson GV, Cole RN, Dong D, Lee M, Hart GW. The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine. J Biol Chem. 271:1996;28741-28744.
30. Ding M, Vandre DD. High molecular weight microtubule-associated proteins contain O-linked-N-acetylglucosamine. J Biol Chem. 271:1996;12555-12561.
31. Dahmus ME. Reversible phosphorylation of the C-terminal domain of RNA polymerase II. J Biol Chem. 271:1996;19009-190012.
32. Dahmus ME. Phosphorylation of mammalian RNA polymerase II. Methods Enzymol. 273:1996;185-193.
33. Comer FI, Hart GW. Investigating the role of O-GlcNAc on RNA polymerase II. FASEB J. 10:1996;A1119.
34. Pazin MJ, Kadonaga JT. What's up and down with histone deacetylation and transcription. of special interest Cell. 89:1997;325-328 A short review of recent findings on histone deacetylation and a few tentative mechanisms by which protein acetylation could regulate transcription.
35. Mizzen CA, Yang XJ, Kokubo T, Brownell JE, Bannister AJ, Owen-Hughes T, Workman J, Wang L, Berger SL, Kouzarides T, et al. The TAF(II)250 subunit of TFIID has histone acetyltransferase activity. Cell. 87:1996;1261-1270.
36. Kotsimbos AT, Humbert M, Minshall E, Durham S, Pfister R, Menz G, Tavernier J, Kay AB, Hamid Q. Upregulation of alpha GM-CSF-receptor in nonatopic asthma but not in atopic asthma. J Allergy Clin Immunol. 99:1997;666-672.
37. Sayed-Ahmed N, Besbas N, Mundy J, Muchaneta-Kubara E, Cope G, Pearson C, el Nahas M. Upregulation of epidermal growth factor and its receptor in the kidneys of rats with streptozotocin-induced diabetes. Exp Nephrol. 4:1996;330-339.
38. Makino I, Shibata K, Ohgami Y, Fujiwara M, Furukawa T. Transient upregulation fo the AT2 receptor mRNA level after global ischemia in the rat brain. Neuropeptides. 30:1996;596-601.
39. Beaulieu M, Brakier-Gingras L, Bouvier M. Upregulation of alpha1A- and alpha1B-adrenergic receptor mRNAs in the heart of cardiomyopathic hamsters. J Mol Cell Cardiol. 29:1997;111-119.
40. Yao GL, Kato H, Khalil M, Kiryu S, Kiyama H. Selective upregulation of cytokine receptor subchain and their intracellular signalling molecules after peripheral nerve injury. Eur J Neurosci. 9:1997;1047-1054.
41. Superti-Furga G, Gonfloni S. A crystal milestone: the structure of regulated Src. Bioessays. 19:1997;447-450.
42. Gram H, Schmitz R, Zuber JF, Baumann G. Identification of phosphopeptide ligands for the Src-homology 2 (SH2) domain of Grb2 by phage display. Eur J Biochem. 246:1997;633-637.
43. Buckhault P, Chen L, Fregien N, Pierce M. Transcriptional regulation of N-acetylglucosaminyltransferase V by the src oncogene. J Biol Chem. 272:1997;19575-19581.
44. Jerome KR, Kirk AD, Pecher G, Ferguson WW, Finn OJ. A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis. Cancer Immunol Immunother. 43:1997;355-360.
45. Regimbald LH, Pilarski LM, Longenecker BM, Reddish MA, Zimmermann G, Hugh JC. The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res. 56:1996;4244-4249.
46. Selzer J, Hofmann F, Rex G, Wilm M, Mann M, Just I, Aktories K. Clostridium novyi alpha-toxin-catalyzed incorporation of GlcNAc into Rho subfamily proteins. J Biol Chem. 271:1996;25173-25177.
47. Aktories K. Bacterial toxins that target Rho proteins. J Clin Invest. 99:1997;827-829.
48. Schwartz LM, Milligan CE. Cold thoughts of death: the role of ICE proteases in neuronal cell death. Trends Neurosci. 19:1996;555-562.
49. Martinou JC, Sadoul R. ICE-like proteases execute the neuronal death program. Curr Opin Neurobiol. 6:1996;609-614.
50. Hisahara S, Shoji S, Okano H, Miura M. ICE/CED-3 family executes oligodendrocyte apoptosis by tumor necrosis factor. J Neurochem. 69:1997;10-20.
51. Jordan J, Galindo MF, Miller RJ. Role of calpain- and interleukin-1 beta converting enzyme-like proteases in the beta-amyloid-induced death of rat hippocampal neurons in culture. J Neurochem. 68:1997;1612-1621.
52. Caputi A, Barindelli S, Pastorino L, Cimino M, Buxbaum JD, Cattabeni F, Di Luca M. Increased secretion of the amino-terminal fragment of amyloid precursor protein in brains of rats with a constitutive up-regulation of protein kinase C. J Neurochem. 68:1997;2523-2529.
53. Lim GP, Russell MJ, Cullen MJ, Tokes ZA. Matrix metalloproteinases in dog brains exhibiting Alzheimer-like characteristics. J Neurochem. 68:1997;1606-1611.
54. Benoist C, Mathis D. Cell death mediators in autoimmune diabetes - no shortage of suspects. of special interest Cell. 89:1997;1-3 This minireview, along with Chervonsky et al. 1997 [55], provides new insight into the mechanisms leading to the death of the insulin-producing β cells of the islets of Langerhans of the pancreas. The papers suggest a direct and an indirect mechanism for T cell mediated Islet β cell death in autoimmune diabetes.
55. Chervonsky AV, Wang Y, Wong FS, Visintin I, Flavell RA, Janeway CA Jr, Matis LA. The role of Fas in autoimmune diabetes. Cell. 89:1997;17-24.
56. Hasselgren PO, Fischer JE. The ubiquitin-proteasome pathway: review of a novel intracellular mechanism of muscle protein breakdown during sepsis and other catabolic conditions. Ann Surg. 225:1997;307-316.
57. Cui H, Matsui K, Omura S, Schauer SL, Matulka RA, Sonenshein GE, Ju ST. Proteasome regulation of activation-induced T cell death. Proc Natl Acad Sci USA. 94:1997;7515-7520.
58. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. of outstanding interest Cancer Res. 56:1996;5309-5318 This paper reviews the importance of aberrant glycosylation of glycosphin-golipids and glycoproteins in defining tumour stage and progression as well as survival rate of patients with cancer. The author also reviews a putative mechanism for the involvement of glycosylation in tumour cell metastasis.
59. Woodburn JR, Barker AJ, Gibson KH, Ashton SE, Wakeling AE, Curry BJ, Scarlett L, Henthorn LR. ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. Proc Am Assoc Cancer Res. 38:1997;633.
60. Klohs W, Steinkampf R, Driscoll D, Kluchko S, Hamby J, Lu G, Vincent P, Roberts B, Elliot W. Characterization of PDGF tyrosine kinase inhibitors in in vitro and in vivo tumors. Proc Am Assoc Cancer Res. 38:1997;632.
61. Fong TAT, McMahon G, Kim Y, Sun L, Tang C, Chen J, Sutton B, Schreck R, Smolich B, Jacobs J, Shawver LK. Small molecule inhibitors of Flk-1 suppress subcutaneous growth of multiple tumor types, inhibit tumor angiogenesis, and provide attenuation of metastasis. Proc Am Assoc Cancer Res. 38:1997;266.
62. Kraker AJ, Moore CW, Amar AM, Shen CS, Nelson J, Slintak V, Fry DW, Lu G, Panek R, Klutchko S, Hamby J. Cytotoxicity and phosphotyrosine effects of c-src kinase inhibition by substituted pyridopyrimidine tyrosine kinase inhibitors in human colon carcinoma cell lines. Proc Am Assoc Cancer Res. 38:1997;633.
63. Crowell PL, Siar Ayoubi A, Burke YD. Anti-tumorigenic effects of limonene and perillyl alcohol against pancreatic and breast cancer. Adv Exp Med Biol. 401:1996;131-136.
64. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med. 2:1996;668-675.
65. Glazer RI. Protein kinase C as a target for cancer therapy. Antisense Nucl Acid Drug Devel. 7:1997;235-238.
66. Bible KC, Kaufmann SH. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res. 56:1996;4856-4861.
67. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 56:1996;2973-2978.
68. Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg. 112:1996;1372-1376. Discussion appears in J Thorac Cardiovasc Surg 1996, 112: 1376-1377.
69. Bottger V, Bottger A, Howard SF, Picksley SM, Chene P, Garcia-Echeverria C, Hochkeppel HK, Lane DP. Identification of novel mdm2 binding peptides by phage display. Oncogene. 13:1996;2141-2147.
70. Beaudry GA, Bertelsen AH, Sherman MI. Therapeutic targeting of the p53 tumor suppressor gene. of outstanding interest Curr Opin Biotechnol. 7:1996;592-600 p53 is the most extensively studied tumour suppressor gene product. This paper lists p53-regulated genes with known or suspected growth regulatory properties. A survey of wild-type p53 and p53 mutations in various cancers and strategies for restoring lost p53 function exemplifies how recently discovered structural and biochemical properties of p53 have led to novel therapeutic strategies.
71. Lopes UG, Erhardt P, Yao R, Cooper GM. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem. 272:1997;12893-12896.
72. Mauss S, Seidlitz B, Jablonowski H, Haussinger D. HIV protease inhibitors. A new drug class in antiretroviral therapy. Dtsch Med Wochenschr. 121:1996;1369-1374.
73. Talbot DC, Brown PD. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer. 32A:1996;2528-2533.
74. Livingston DJ. In vitro and in vivo studies of ICE inhibitors. of outstanding interest J Cell Biochem. 64:1997;19-26 This article reviews the mechanism of action and pharmacology of various inhibitors of interleukin-β converting enzymes (ICE) and related proteases as a new strategy to treat chronic inflammatory and neurodegenerative diseases.